Director Commercial Project Management & Launch Excellence
Remix Therapeutics
Director Commercial Project Management & Launch Excellence
Remix Therapeutics
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).
In June 2026, Remix announced an agreement to merge with Passage Bio, with the combined company expected to operate as Remix Therapeutics and trade on Nasdaq. The announced transaction included a concurrent $100 million private placement intended to support continued development of its pipeline. Remix remains focused on translating its RNA-processing science into meaningful treatment options for patients with significant unmet medical needs.
Position Summary:
The Director will translate commercial strategy into an actionable enterprise launch plan, align stakeholders around priorities, and drive accountability for delivery. Working closely with Commercial, Medical Affairs, Clinical Development, Regulatory, Market Access, Technical Operations, Quality, Finance, Legal and Compliance, IT, and Human Resources, this individual will connect workstreams, surface risks, and help leadership make timely decisions.
This is a hands-on role for a leader who can build practical processes, influence without direct authority, and move comfortably between strategic planning and detailed execution. The Director owns integrated launch management, working with functional leaders who remain accountable for their strategies and deliverables.
This is an opportunity to help lead the integrated planning, coordination, execution, and tracking of the potential launch of REM-422, subject to regulatory approval.
Key Responsibilities:
Qualifications:
Salary Range:
$206,000 - $252,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.
Biotech firm developing mRNA-degrading therapies
Remix Therapeutics develops medicines for rare diseases by using targeted degradation of mRNA with an oral small molecule. Its lead candidate REM 422 degrades messenger RNA to stop production of disease-causing proteins and is in Phase 1 trials for ACC and AML, with FDA Orphan Drug designation. The company funds R&D through grants, partnerships, and eventual commercialization, leveraging collaborations with larger pharma. Its goal is to deliver safe and effective medicines for rare cancers and genetic disorders by advancing REM 422 and expanding its portfolio to address unmet medical needs.
Explore more opportunities at Remix Therapeutics